Has Ed Sheeran confirmed using Ozempic, Wegovy, or any GLP-1 drug?

No. Ed Sheeran has not publicly confirmed using any GLP-1 receptor agonist. He has attributed his weight loss to exercise and dietary changes. All association between Sheeran and GLP-1 medications is public speculation.

How much does a GLP-1 medication cost without insurance?

At list price, Wegovy costs approximately $1,350 per month and Zepbound approximately $1,060 per month. Patient assistance programs and compounded alternatives may reduce this for qualifying individuals.

Will my insurance cover Wegovy or Zepbound for weight loss?

Coverage depends on your specific plan. Many commercial plans require prior authorization with documentation of BMI thresholds and failed lifestyle interventions. Medicare coverage remains limited to cardiovascular risk reduction indications. Fewer than 15 state Medicaid programs broadly cover anti-obesity medications.

What happens if I stop taking a GLP-1 medication?

Clinical trial data shows that patients regain approximately two-thirds of lost weight within 12 months of discontinuation. The STEP 1 extension data documented this pattern clearly, which is why the HealthRX Medical Team recommends planning for sustained treatment when budgeting.

Is compounded semaglutide safe?

Compounded semaglutide from registered 503B outsourcing facilities may be acceptable, but quality varies. The FDA has flagged adverse events from products with incorrect concentrations. Patients should request batch certificates of analysis and work with a prescribing clinician who monitors treatment response.

What Ed Sheeran's GLP-1 Protocol Would Cost Outside a Celebrity Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Ed Sheeran Has Actually Said

Between 2023 and 2025, Ed Sheeran appeared noticeably leaner in public appearances and concert footage. In interviews, he credited the change to consistent exercise routines and cutting back on alcohol and processed food. He has not disclosed use of semaglutide, tirzepatide, or any other GLP-1 medication. No credible report from his representatives or medical team has confirmed GLP-1 use.

The speculation emerged largely on social media, where fans and commentators noted that Sheeran's timeline of visible change coincided with the broader surge in GLP-1 prescriptions among public figures. That timing alone does not constitute evidence. The HealthRX Medical Team treats this as speculated use only, and every clinical discussion below applies to the drug class in general, not to Sheeran's personal medical history.

The GLP-1 Drugs at the Center of the Conversation

The two FDA-approved GLP-1 receptor agonists most commonly discussed in the context of celebrity weight loss are semaglutide (branded as Wegovy for weight management and Ozempic for type 2 diabetes) and tirzepatide (branded as Zepbound for weight management and Mounjaro for type 2 diabetes). Both are injectable, administered weekly via a prefilled pen.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, increasing insulin secretion in a glucose-dependent manner, and acting on hypothalamic appetite centers to reduce caloric intake. Tirzepatide adds a second mechanism: it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor, which may amplify its effects on insulin sensitivity and body weight. In the SURMOUNT-1 trial, tirzepatide at the highest dose produced mean weight loss of 22.5% over 72 weeks in participants without diabetes. Semaglutide 2.4 mg produced roughly 15% mean weight loss at 68 weeks in the STEP 1 trial.

List Price: The Number That Stops Most Conversations

As of early 2026, the wholesale acquisition cost (WAC) for a one-month supply of Wegovy sits near $1,350. Zepbound lists at approximately $1,060 per month. These are pre-insurance figures, and for patients paying out of pocket, they represent a recurring monthly expense that compounds over treatment durations typically measured in years.

A 12-month course of Wegovy at list price runs roughly $16,200. For Zepbound, the figure is approximately $12,720. These numbers exclude office visits, lab work (lipid panels, HbA1c, renal function), and the dose-escalation period during which patients may use lower-dose pens at a marginally reduced cost.

The HealthRX Medical Team's cost-access framework for GLP-1 therapy:

| Cost Component | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) | |---|---|---| | Monthly WAC (list price) | ~$1,350 | ~$1,060 | | Annual WAC | ~$16,200 | ~$12,720 | | Typical insured copay (preferred formulary) | $25 to $150/mo | $25 to $150/mo | | Copay with manufacturer savings card | $0 to $25/mo (commercially insured) | $0 to $25/mo (commercially insured) | | Compounded semaglutide (where available) | $100 to $400/mo | N/A (limited compounding) | | Required labs (annual estimate) | $200 to $600 | $200 to $600 |

These figures shift with formulary changes. Patients should verify current tier placement with their specific plan.

Insurance Coverage: A Patchwork, Not a Guarantee

Commercial insurance coverage for GLP-1 weight-management indications varies dramatically by employer and plan. A 2024 analysis from the Peterson-KFF Health System Tracker found that fewer than half of large employer plans covered anti-obesity medications without prior authorization, and many imposed step-therapy requirements (documented failure of diet and exercise, minimum BMI thresholds, sometimes prior use of older agents like phentermine).

Medicare Part D, as of the Inflation Reduction Act provisions taking effect through 2025 and 2026, has begun limited coverage for semaglutide when prescribed for cardiovascular risk reduction following the SELECT trial results showing a 20% reduction in major adverse cardiovascular events. Pure weight-management indications under Medicare remain restricted. Medicaid coverage is state-dependent, with fewer than 15 state Medicaid programs offering broad anti-obesity medication coverage as of early 2026.

Prior authorization is nearly universal. Patients should expect to provide documentation of BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea), evidence of a structured diet-and-exercise program, and sometimes lab results confirming metabolic dysfunction. Denials are common on first submission. Appeals succeed at meaningful rates when accompanied by physician letters citing AGA clinical guidelines or the Endocrine Society's 2024 obesity pharmacotherapy recommendations.

Manufacturer Savings Programs and Their Limits

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) operate copay savings cards that can reduce the out-of-pocket cost to $0 to $25 per month for commercially insured patients. These programs exclude patients on government insurance (Medicare, Medicaid, Tricare). They also carry annual caps, typically $150 to $200 per fill with a maximum annual benefit between $3,000 and $5,000.

For uninsured patients, Novo Nordisk's patient assistance program offers Wegovy at no cost for qualifying households under 400% of the federal poverty level. Lilly's program has similar income thresholds. The application process takes 4 to 8 weeks, and patients must requalify annually.

Compounded Semaglutide: Lower Cost, Higher Risk

The FDA's temporary shortage designation for semaglutide allowed 503A and 503B compounding pharmacies to produce generic semaglutide at prices between $100 and $400 per month. As shortage designations shift, the regulatory status of compounded versions changes. Patients using compounded products face variable quality control, inconsistent dosing accuracy, and no manufacturer-backed adverse-event monitoring. The FDA has issued warnings about adverse events linked to compounded semaglutide products containing incorrect concentrations or non-pharmaceutical-grade ingredients.

The HealthRX Medical Team advises that patients considering compounded GLP-1 products verify the pharmacy's 503B outsourcing facility registration, request certificates of analysis for each batch, and discuss the decision with a prescribing clinician who can monitor for expected dose-response patterns.

Side Effects That Add Hidden Costs

Common GLP-1 side effects create their own cost burden. Nausea, vomiting, and diarrhea affect 40% to 50% of patients during dose escalation. Ondansetron prescriptions, dietary supplements to manage GI symptoms, and additional physician visits during titration add $50 to $200 per month in incidental costs during the first 8 to 16 weeks.

Less common but clinically significant: pancreatitis risk (rare, estimated at <0.5% based on post-marketing data), gallbladder events in 1% to 2% of patients on higher doses, and potential lean-mass loss that may require supervised resistance training or protein supplementation to mitigate. A 2023 JAMA study highlighted that approximately one-third of weight lost on semaglutide was lean mass, a ratio that structured exercise programs can improve.

What the HealthRX Medical Team Thinks

Ed Sheeran has publicly attributed his physical changes to exercise and diet, and no evidence contradicts that account. The speculation around his potential GLP-1 use says more about public perception of these drugs than about Sheeran himself.

What matters clinically is that GLP-1 medications work. The trial data is strong and reproducible. The access problem is real and ongoing. A patient without celebrity-level resources faces a system where the drug might cost $1,350 per month at list price, insurance coverage depends on which employer happens to sponsor their plan, prior authorizations require documentation that many primary care offices struggle to compile quickly, and compounded alternatives carry regulatory and quality uncertainty.

The cost conversation is not separate from the medical conversation. Treatment discontinuation rates for GLP-1 medications are high, with real-world data suggesting that roughly 40% to 70% of patients stop within the first year. Cost and access barriers are among the top reasons cited. Weight regain after discontinuation is well-documented: the STEP 1 extension trial showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide.

For patients considering GLP-1 therapy, the HealthRX Medical Team recommends: verify your insurance formulary before the first prescription is written, apply for manufacturer savings cards on the same day as the initial consultation, ask your physician about prior-authorization templates that cite cardiovascular benefit data, and plan for a minimum 12-month treatment window when budgeting, because shorter courses correlate with higher regain rates.

At a glance

Ed Sheeran's GLP-1 use is speculated, not confirmed. He has credited exercise and dietary changes for his weight loss.
Wegovy lists at ~$1,350/month; Zepbound at ~$1,060/month. Annual costs exceed $12,000 to $16,000 without insurance.
Insurance coverage is inconsistent. Prior authorization is almost always required, and denials on first attempt are common.
Manufacturer copay cards can reduce costs to $0 to $25/month for commercially insured patients, but exclude Medicare and Medicaid.
Compounded semaglutide runs $100 to $400/month but carries regulatory and quality risks.
Discontinuation rates are 40% to 70% in the first year, with cost frequently cited as a primary driver.

Frequently asked questions

›